Anti-Diabetes Drugs - Zimbabwe | Statista Market Forecast

The projected revenue for Zimbabwe in the Anti-Diabetes Drugs market is expected to reach US$5.36m in 2024.
Furthermore, it is anticipated that the revenue will experience an annual growth rate of 5.53% (CAGR 2024-2029), leading to a market volume of US$7.01m by 2029.
It is worth noting that in a global comparison, United States is estimated to generate the highest revenue in the market, with an expected value of US$37.84bn in 2024.
Zimbabwe has witnessed a surge in demand for innovative anti-diabetes drugs, as the government focuses on improving healthcare infrastructure.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The prevalence of diabetes in Zimbabwe has increased significantly over the past few decades, leading to a growing demand for anti-diabetes drugs in the country.

Customer preferences: Patients in Zimbabwe prefer oral anti-diabetes drugs over insulin injections due to the convenience and ease of use. The affordability of drugs is also a key factor for many patients, leading to a preference for generic versions of drugs.

Trends in the market: The market for anti-diabetes drugs in Zimbabwe is growing steadily, driven by the increasing prevalence of diabetes in the country. The market is dominated by multinational pharmaceutical companies, which have a strong presence in the country. However, there is also a growing market for locally produced generic drugs, which are often more affordable for patients.

Local special circumstances: The healthcare system in Zimbabwe faces significant challenges, including a lack of resources and infrastructure. This has led to a shortage of healthcare professionals and limited access to healthcare services for many people in the country. As a result, many patients with diabetes may not receive adequate treatment or may not be diagnosed until the disease has progressed significantly.

Underlying macroeconomic factors: Zimbabwe has experienced significant economic challenges in recent years, including high inflation and a shortage of foreign currency. This has led to challenges in the healthcare sector, including shortages of drugs and medical supplies. Additionally, the COVID-19 pandemic has had a significant impact on the economy and the healthcare system, leading to further challenges for patients with diabetes. Despite these challenges, the market for anti-diabetes drugs in Zimbabwe is expected to continue to grow in the coming years, driven by the increasing prevalence of diabetes in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.